Abstract
Language | English |
---|---|
Article number | j5096 |
Number of pages | 5 |
Journal | British Medical Journal |
Volume | 359 |
DOIs | |
Publication status | Published - 10 Nov 2017 |
Fingerprint
Keywords
- medical economics
- medical costs
- NICE guidance
Cite this
}
Should cost effectiveness analyses for NICE always consider future unrelated medical costs? / van Baal, Pieter; Morton, Alec; Brouwer, Werner; Meltzer, David; Davis, Sarah.
In: British Medical Journal, Vol. 359, j5096 , 10.11.2017.Research output: Contribution to journal › Article
TY - JOUR
T1 - Should cost effectiveness analyses for NICE always consider future unrelated medical costs?
AU - van Baal, Pieter
AU - Morton, Alec
AU - Brouwer, Werner
AU - Meltzer, David
AU - Davis, Sarah
PY - 2017/11/10
Y1 - 2017/11/10
N2 - When developing guidance on the use of new technologies within the NHS, NICE recommends the use of cost effectiveness. Specifically, an intervention is deemed cost effective by NICE if ‘its health benefits are greater than the opportunity costs of programmes displaced to fund the new technology, in the context of a fixed NHS budget. In other words, the general consequences for the wider group of patients in the NHS are considered alongside the effects for those patients who may directly benefit from the technology.’ We argue that the technical guidelines for health technology assessment used by NICE should change given this definition of cost effectiveness. The point at issue is the handling of “unrelated future medical costs”.
AB - When developing guidance on the use of new technologies within the NHS, NICE recommends the use of cost effectiveness. Specifically, an intervention is deemed cost effective by NICE if ‘its health benefits are greater than the opportunity costs of programmes displaced to fund the new technology, in the context of a fixed NHS budget. In other words, the general consequences for the wider group of patients in the NHS are considered alongside the effects for those patients who may directly benefit from the technology.’ We argue that the technical guidelines for health technology assessment used by NICE should change given this definition of cost effectiveness. The point at issue is the handling of “unrelated future medical costs”.
KW - medical economics
KW - medical costs
KW - NICE guidance
UR - http://www.bmj.com/archive
U2 - 10.1136/bmj.j5096
DO - 10.1136/bmj.j5096
M3 - Article
VL - 359
JO - BMJ
T2 - BMJ
JF - BMJ
SN - 0959-8138
M1 - j5096
ER -